Business Wire

CA-FORESCOUT-TECHNOLOGIE

13.1.2024 15:53:28 CET | Business Wire | Pressemeddelelse

Del
Sandworm har ikke alene skylden: Forescout Research afdækker nye beviser for cyberangreb på energisektoren i Danmark

Forescout, en global leder inden for cybersikkerhed løftede i dag sløret for "Clearing the Fog of War", en rapport, der præsenterer nye beviser for to tidligere dokumenterede angreb, der ramte den danske energisektor i maj 2023.

Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20240110894177/da/

For at se dette indhold fra mms.businesswire.com, så skal du give din accept på toppen af denne side.

Clearing the Fog of War (Source: Forescout)

Forescout Research – Vedere Labs gennemførte en uafhængig analyse af disse angreb og afslørede en større kampagne, der ikke fuldt ud kunne tilskrives Advanced Persistent Threat-gruppen Sandworm, sammen med andre fund, som det danske cybersikkerhedscenter SektorCERT ikke offentliggjorde i sin rapport fra november 2023.

I sine observationer af Adversary Engagement Environment (AEE) identificerede Vedere Labs to vigtige resultater:

  • Sandworm er ikke den fælles trusselsaktør: Forescout-forskerne påviste en anden teknik til at ramme den kritiske infrastruktur i den efterfølgende bølge end den, der blev brugt i første angrebsbølge. Dette tyder på, at Sandworm ikke kan udpeges som den APT-gruppe, der er forbundet med begge angrebsbølger.
  • Masseudnyttelse blev videreført af en copycat: Den anden bølge af angreb udnyttede upatchede firewalls ved hjælp af en ny "populær" CVE-2023-27881 og yderligere IP-adresser, der ikke blev rapporteret i SektorCERT-rapporten. Meget tyder på, at den anden bølge var en del af en separat masseudnyttelseskampagne.

"At skelne mellem en statsstøttet kampagne, der har til formål at forstyrre kritisk infrastruktur, og en kriminel bølge af masseudnyttelseskampagner, samtidig med at man tager højde for potentielle overlap mellem de to, er nemmere set i bakspejlet end i øjeblikkets hede," bemærker Elisa Costante, VP of Research hos Forescout Research – Vedere Labs. "Denne rapport understreger betydningen af at kontekstualisere observerede hændelser med omfattende trussels- og sårbarhedsefterretninger med henblik på at forbedre OT-netværksovervågning og udvikle bedre hændelsesresponsplaner."

Læs bloggen: Clearing the Fog of War – En kritisk analyse af de seneste cyberangreb på energisektoren i Danmark og Ukraine

Efter den anden hændelse blev yderligere angreb i de efterfølgende måneder rettet mod udsatte enheder i kritiske infrastrukturer verden over. Forescout-forskere registrerede adskillige IP-adresser, der forsøgte at udnytte Zyxel-sårbarheden CVE-2023-28771, så sent som i oktober 2023, på tværs af forskellige enheder, herunder yderligere Zyxel-firewalls. I øjeblikket bruger seks forskellige elselskaber i europæiske lande Zyxel-firewalls, og de kan således fortsat være følsomme over for potentiel udnyttelse af ondsindede aktører.

Denne nyere dokumentation understreger nødvendigheden af, at energivirksomheder og organisationer, der fører tilsyn med kritisk infrastruktur, er opmærksomme på aktuelle trusselsefterretninger, herunder oplysninger om ondsindede IP'er og kendte udnyttede sårbarheder. Regeringer tager i stigende grad proaktive forholdsregler ved at afsætte midler til initiativer, der har til formål at styrke sikkerheden for kritisk infrastruktur inden for energisektoren. Navnlig har det amerikanske energiministerium annonceret et nyt finansieringsinitiativ og øremærket 70 millioner dollars til dette formål så sent som i sidste uge.

Forescout Research gennemførte denne analyse ved hjælp af deres AEE, som omfatter både virkelige og simulerede forbundne enheder. Dette miljø fungerer som et dybdegående værktøj til at lokalisere hændelser og skelne mellem trusselsaktørers mønstre på et højt detaljeret niveau. Målet er at forbedre reaktionerne på komplicerede angreb på kritisk infrastruktur ved hjælp af den dybere indsigt og forståelse, der opnås fra dette specialiserede testmiljø.

Flere oplysninger kan findes i den fulde rapport, "Clearing the Fog of War".

Om Forescout

Forescout Technologies, Inc. er en global leder inden for cybersikkerhed, der løbende identificerer, beskytter og hjælper med at sikre overholdelse af alle administrerede og ikke-administrerede forbundne cyberaktiver – IT, IoT, IoMT og OT. Gennem mere end 20 år har Fortune 100-organisationer og offentlige myndigheder betroet Forescout at stille leverandøruafhængig, automatiseret cybersikkerhed til rådighed i stor skala. Forescout®-platformen leverer omfattende løsninger inden for netværkssikkerhed, risiko- og eksponeringsstyring samt udvidet detektion og respons. Med gnidningsfri kontekstdeling og workflow-orkestrering via økosystempartnere giver det kunderne mulighed for mere effektivt at håndtere cyberrisici og afværge trusler.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240110894177/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye